Safety And Effectiveness Of Genetic Testing In Treatment Of Essential Hypertension In Tangshan

Objectives This study aims to the Tangshan area of primary hypertension individualized hypertension genetic test results,guide antihypertensive treatment,and remote follow-up medical management,evaluate hypertension precision medication to clinic blood pressure success rate and improvement rate,heart rate,adverse reactions(cough,dizziness,edema),cardiovascular events,sugar,lipid metabolism rate,etc.,to achieve hypertension precision medication,and provide evidence to support.Methods With the informed consent of the patients and their families,the number of essential hypertension patients diagnosed and established in the Cardiology Department of Tangshan Central Hospital from January 2020 to January 2021 was 160.Patients with essential hypertension diagnosed after testing hypertension hormones,routine urine,perfect renal vascular and adrenal ultrasound,and cardiac ultrasound.Patients will be randomized into 2 groups.The experimental group conducted individualized pharmacogenetic testing for hypertension under guidance,including 80 cases,and the routine group conducted preliminary determination based on clinical experience,including80 cases.General data between the experimental group and the control group,changes in the outpatient BP rate,incidence of adverse reactions(cough,dizziness,edema),major adverse cardiovascular events(MACE),fasting blood glucose(FBG),cholesterol(TC)and triglycerides(TG).Objective To investigate the therapeutic value of genetic testing of hypertension in patients with essential hypertension.Results 1 There was no significant difference in the blood pressure level between the two groups before treatment,and the genetic guidance group was significantly lower than that before treatment,and better than the non-genetic guidance group(P<0.05).2 The overall response rate of BP therapy in the genetic guidance group was higher than that in the non-genetic guidance group(P<0.05).3 To compare the incidence of adverse drug reactions in the two hypertensive groups: dizziness,dry cough and edema.The incidence of adverse drug reactions in the genetic guidance group was 5.0%,which was better than23.0% in the non-genetic guidance group.The difference was statistically significant(P<0.05).4 There was no significant difference in fasting blood glucose(FBG),cholesterol(TC),and triglyceride(TG)decrease between the two groups.5 AIS 8,AIS 1,significant difference(P<0.05).The genetic guidance group had angina pectoris 1,0 cardiac death,0,0myocardial reinfarction,and 0 rehospitalization for acute coronary syndrome.Nongenic guidance group angina pectoris 5,cardiac death 0,myocardial reinfarction 2,0rehospitalization for acute coronary syndrome,heart failure 1,in 8 cases.MACE events compared the two groups(P<0.05).Conclusions Compared with traditional clinical experience,genetic testing-guided medication can make patients with essential hypertension in Tangshan achieve the ideal blood pressure earlier,reduce the incidence of adverse drug reactions,improve the treatment efficiency,and reduce the occurrence of cardiac and cerebrovascular events.Figure 0;Table 6;Reference 113...